{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:25:16Z","timestamp":1770218716455,"version":"3.49.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1007\/s10557-006-0498-3","type":"journal-article","created":{"date-parts":[[2006,11,27]],"date-time":"2006-11-27T07:34:28Z","timestamp":1164612868000},"page":"377-386","source":"Crossref","is-referenced-by-count":25,"title":["New Insights in the Treatment Strategy for Pulmonary Arterial Hypertension"],"prefix":"10.1007","volume":"20","author":[{"given":"Makoto","family":"Sahara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunobu","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryozo","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,11,23]]},"reference":[{"key":"10498_CR1","doi-asserted-by":"crossref","first-page":"51A","DOI":"10.1016\/S0002-9149(99)80383-X","volume":"75","author":"LJ Rubin","year":"1995","unstructured":"Rubin LJ. Pathology and pathophysiology of primary pulmonary hypertension. Am J Cardiol 1995;75:51A\u20134.","journal-title":"Am J Cardiol"},{"key":"10498_CR2","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1161\/01.CIR.102.22.2781","volume":"102","author":"S Archer","year":"2000","unstructured":"Archer S, Rich S. Primary pulmonary hypertension: a vascular biology and translational research \u201cwork in progress\u201d. Circulation 2000;102:2781\u201391.","journal-title":"Circulation"},{"key":"10498_CR3","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S0140-6736(03)13167-4","volume":"361","author":"JR Runo","year":"2003","unstructured":"Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003;361:1533\u201344.","journal-title":"Lancet"},{"key":"10498_CR4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJM199701093360207","volume":"336","author":"LJ Rubin","year":"1997","unstructured":"Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336:111\u20137.","journal-title":"N Engl J Med"},{"key":"10498_CR5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0008-6363(97)00053-9","volume":"34","author":"M Rabinovitch","year":"1997","unstructured":"Rabinovitch M. Pulmonary hypertension: updating a mysterious disease. Cardiovasc Res 1997;34:268\u201372.","journal-title":"Cardiovasc Res"},{"key":"10498_CR6","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra035488","volume":"351","author":"HW Farber","year":"2004","unstructured":"Farber HW, Loscalzo JL. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655\u201365.","journal-title":"N Engl J Med"},{"key":"10498_CR7","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1165\/ajrcmb.23.6.4106","volume":"23","author":"C Partovian","year":"2000","unstructured":"Partovian C, Adnot S, Raffestin B, Louzier V, Levame M, Mavier IM, et al. Adenovirus-mediated lung vascular endothelial growth factor overexpression protects against hypoxic pulmonary hypertension in rats. Am J Respir Cell Mol Biol 2000;23:762\u201371.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10498_CR8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM199507273330403","volume":"333","author":"A Giaid","year":"1995","unstructured":"Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995;333:214\u201321.","journal-title":"N Engl J Med"},{"key":"10498_CR9","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","volume":"328","author":"A Giaid","year":"1993","unstructured":"Giaid A, Yanagisawa M, Langleben D, Michel R, Levy H, Shennib S, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732\u201339.","journal-title":"N Engl J Med"},{"key":"10498_CR10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","volume":"327","author":"BW Christman","year":"1992","unstructured":"Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327:70\u20135.","journal-title":"N Engl J Med"},{"key":"10498_CR11","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1164\/rccm.2208008","volume":"166","author":"LJ Rubin","year":"2002","unstructured":"Rubin LJ. Therapy of pulmonary hypertension: the evolution from vasodilators to antiproliferative agents. Am J Respir Crit Care Med 2002;166:1308\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"10498_CR12","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","volume":"334","author":"RJ Barst","year":"1996","unstructured":"Barst RJ, Rubin LJ, Long WA, McGoon M, Rich S, Badesch D, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296\u2013302.","journal-title":"N Engl J Med"},{"key":"10498_CR13","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","volume":"106","author":"VV McLaughlin","year":"2002","unstructured":"McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477\u201382.","journal-title":"Circulation"},{"key":"10498_CR14","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","volume":"346","author":"LJ Rubin","year":"2002","unstructured":"Rubin LJ, Badesch DB, Barst LJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896\u2013903.","journal-title":"N Engl J Med"},{"key":"10498_CR15","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMra040291","volume":"351","author":"M Humbert","year":"2004","unstructured":"Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425\u201336.","journal-title":"N Engl J Med"},{"key":"10498_CR16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","volume":"327","author":"S Rich","year":"1992","unstructured":"Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76\u201381.","journal-title":"N Engl J Med"},{"key":"10498_CR17","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1183\/09031936.98.12020265","volume":"12","author":"O Sitbon","year":"1998","unstructured":"Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998;12:265\u201370.","journal-title":"Eur Respir J"},{"key":"10498_CR18","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/263663a0","volume":"263","author":"S Moncada","year":"1976","unstructured":"Moncada S, Gryglewsli R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263:663\u20135.","journal-title":"Nature"},{"key":"10498_CR19","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1165\/ajrcmb.26.2.4695","volume":"26","author":"LH Clapp","year":"2002","unstructured":"Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, Tinker A. Differential effects of stable prostacyclin analogues on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 2002;26:194\u2013201.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10498_CR20","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","volume":"40","author":"O Sitbon","year":"2002","unstructured":"Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"10498_CR21","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1183\/09031936.99.13613579","volume":"13","author":"M Humbert","year":"1999","unstructured":"Humbert M, Sanchez O, Fartoukh M, Jagot JL, Le Gall C, Sitbon O, et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J 1999;13:1351\u20136.","journal-title":"Eur Respir J"},{"key":"10498_CR22","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","volume":"165","author":"G Simonneau","year":"2002","unstructured":"Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge R, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind randomized controlled trial. Am J Respir Crit Care Med 2002;165:800\u20134.","journal-title":"Am J Respir Crit Care Med"},{"key":"10498_CR23","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0735-1097(02)01786-2","volume":"39","author":"N Galie","year":"2002","unstructured":"Galie N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind placebo-controlled trial. J Am Coll Cardiol 2002;39:1496\u20131502.","journal-title":"J Am Coll Cardiol"},{"key":"10498_CR24","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","volume":"347","author":"H Olschewski","year":"2002","unstructured":"Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije MD, Rubin L, et al. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med 2002;347:322\u20137.","journal-title":"N Engl J Med"},{"key":"10498_CR25","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/332411a0","volume":"332","author":"M Yanagisawa","year":"1988","unstructured":"Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411\u20135.","journal-title":"Nature"},{"key":"10498_CR26","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/rr44","volume":"2","author":"KA Fagan","year":"2001","unstructured":"Fagan KA, McMurtry IF, Rodman DM. Role of endothelin-1 in lung disease. Respir Res 2001;2:90\u2013101.","journal-title":"Respir Res"},{"key":"10498_CR27","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","volume":"358","author":"RN Channick","year":"2001","unstructured":"Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119\u201323.","journal-title":"Lancet"},{"key":"10498_CR28","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1378\/chest.124.1.247","volume":"124","author":"O Sitbon","year":"2003","unstructured":"Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003;124:247\u201354.","journal-title":"Chest"},{"key":"10498_CR29","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1378\/chest.123.4.989","volume":"123","author":"S Mehta","year":"2003","unstructured":"Mehta S. Sildenafil for pulmonary arterial hypertension: exciting, but protection required. Chest 2003;123:989\u201392.","journal-title":"Chest"},{"key":"10498_CR30","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/0140-6736(91)92033-X","volume":"338","author":"J Pepke-Zaba","year":"1991","unstructured":"Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991;338:1173\u20134.","journal-title":"Lancet"},{"key":"10498_CR31","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1161\/01.CIR.101.17.2066","volume":"101","author":"T Hasuda","year":"2000","unstructured":"Hasuda T, Satoh T, Shimouchi A, Sakamaki F, Kyotani S, Matsumoto T, et al. Improvement in exercise capacity with nitric oxide inhalation in patients with precapillary pulmonary hypertension. Circulation 2000;101:2066\u201370.","journal-title":"Circulation"},{"key":"10498_CR32","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/hc3601.096826","volume":"104","author":"H Wilkens","year":"2001","unstructured":"Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104:1218\u201322.","journal-title":"Circulation"},{"key":"10498_CR33","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(02)11024-5","volume":"360","author":"HA Ghofrani","year":"2002","unstructured":"Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002;360:895\u2013900.","journal-title":"Lancet"},{"key":"10498_CR34","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0735-1097(03)00555-2","volume":"42","author":"HA Ghofrani","year":"2003","unstructured":"Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003;42:158\u201364.","journal-title":"J Am Coll Cardiol"},{"key":"10498_CR35","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM200011023431814","volume":"343","author":"S Prasad","year":"2000","unstructured":"Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med 2000;343:1342.","journal-title":"N Engl J Med"},{"key":"10498_CR36","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1378\/chest.123.4.1293","volume":"123","author":"L Stiebellehner","year":"2003","unstructured":"Stiebellehner L, Petkov V, Vonbank K, Funk G, Schenk P, Ziesche R, et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest 2003;123:1293\u20135.","journal-title":"Chest"},{"key":"10498_CR37","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1161\/01.CIR.0000099502.17776.C2","volume":"108","author":"ED Michelakis","year":"2003","unstructured":"Michelakis ED, Tymchak W, Noga M, Webster L, Wu X-C, Lien D, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003;108:2066\u20139.","journal-title":"Circulation"},{"key":"10498_CR38","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2003.10.056","volume":"43","author":"BK Sastry","year":"2004","unstructured":"Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004;43:1149\u201353.","journal-title":"J Am Coll Cardiol"},{"key":"10498_CR39","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","volume":"353","author":"N Galie","year":"2005","unstructured":"Galie N, Ghofrani HA, Torbicki A, Barst R, Rubin L, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148\u201357.","journal-title":"N Engl J Med"},{"key":"10498_CR40","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/sj.bjp.0704984","volume":"137","author":"F Murray","year":"2002","unstructured":"Murray F, MacLean MR, Pyne NJ. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol 2002;37:1187\u201394.","journal-title":"Br J Pharmacol"},{"key":"10498_CR41","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1046\/j.1474-8673.2003.00284.x","volume":"23","author":"A Tasatargil","year":"2003","unstructured":"Tasatargil A, Sadan G, Ozdem SS. The effects of selective phosphodiesterase III and V inhibitors on adrenergic and non-adrenergic, non-cholinergic relaxation responses of guinea-pig pulmonary arteries. Auton Autacoid Pharmacol 2003;23:117\u201324.","journal-title":"Auton Autacoid Pharmacol"},{"key":"10498_CR42","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1253\/circj.66.149","volume":"66","author":"Effects of Pimobendan on Chronic Heart Failure Study (EPOCH Study)","year":"2002","unstructured":"Effects of Pimobendan on Chronic Heart Failure Study (EPOCH Study). Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). Circ J 2002;66:149\u201357.","journal-title":"Circ J"},{"key":"10498_CR43","doi-asserted-by":"crossref","first-page":"18J","DOI":"10.1016\/0002-9149(89)90200-2","volume":"63","author":"N Taira","year":"1989","unstructured":"Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol 1989;63:18J\u201324J.","journal-title":"Am J Cardiol"},{"key":"10498_CR44","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/0002-9149(95)80029-R","volume":"75","author":"M Hongo","year":"1995","unstructured":"Hongo M, Takenaka H, Uchikawa S, Nakatsuka T, Watanabe N, Sekiguchi M. Coronary microvascular response to intracoronary administration of nicorandil. Am J Cardiol 1995;75:246\u201350.","journal-title":"Am J Cardiol"},{"key":"10498_CR45","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00005344-199510000-00006","volume":"26","author":"K Akai","year":"1995","unstructured":"Akai K, Wang Y, Sato K, Sekiguchi N, Sugimura A, Kumagai T, et al. Vasodilatory effect of nicorandil on coronary arterial microvessels: its dependency on vessel size and the involvement of the ATP-sensitive potassium channels. J Cardiovasc Pharmacol 1995;26:541\u20137.","journal-title":"J Cardiovasc Pharmacol"},{"key":"10498_CR46","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/BF00877622","volume":"7","author":"T Yanagisawa","year":"1993","unstructured":"Yanagisawa T, Yamagishi T, Okada Y. Hyperpolarization induced by K+ channel openers inhibits Ca2+ influx and Ca2+ release in coronary artery. Cardiovasc Drugs Ther 1993;7:565\u201374.","journal-title":"Cardiovasc Drugs Ther"},{"key":"10498_CR47","first-page":"H2607","volume":"272","author":"JE Schultz","year":"1997","unstructured":"Schultz JE, Yao Z, Cavero I, Gross GJ. Glibenclamide-induced blockade of ischemic preconditioning is time dependent in intact rat heart. Am J Physiol 1997;272:H2607\u201315.","journal-title":"Am J Physiol"},{"key":"10498_CR48","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0735-1097(99)00552-5","volume":"35","author":"T Sato","year":"2000","unstructured":"Sato T, Sasaki N, O\u2019Rourke B, Marban E. Nicorandil, a potent cardioprotective agent, acts by opening mitochondrial ATP-dependent potassium channels. J Am Coll Cardiol 2000;35:514\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"10498_CR49","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/01.fjc.0000176728.74690.09","volume":"46","author":"M Hongo","year":"2005","unstructured":"Hongo M, Mawatari E, Sakai A, Zonghai R, Koizumi T, Terasawa F, et al. Effects of nicorandil on monocrotaline-induced pulmonary arterial hypertension in rats. J Cardiovasc Pharmacol 2005;46:452\u20138.","journal-title":"J Cardiovasc Pharmacol"},{"key":"10498_CR50","doi-asserted-by":"crossref","first-page":"I3","DOI":"10.1002\/clc.4960271303","volume":"27","author":"AM Hutter Jr","year":"2004","unstructured":"Hutter AM Jr. Role of the cardiologist: clinical aspects of managing erectile dysfunction. Clin Cardiol 2004;27:I3\u20137.","journal-title":"Clin Cardiol"},{"key":"10498_CR51","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00005344-199901000-00014","volume":"33","author":"T Kamijo","year":"1999","unstructured":"Kamijo T, Kamei K, Sugo I, Kamiyama T, Sudo H, Ohba Y. Hemodynamic and hormonal responses to nicorandil in a canine model of acute ischemic heart failure: a comparison with cromakalim and nitroglycerin. J Cardiovasc Pharmacol 1999;33:93\u2013101.","journal-title":"J Cardiovasc Pharmacol"},{"key":"10498_CR52","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1183\/09031936.03.00054103","volume":"22","author":"M Humbert","year":"2003","unstructured":"Humbert M, Sitbon O, Simonneau G. Novel therapeutic perspectives in pulmonary arterial hypertension. Eur Respir J 2003;22:193\u20134.","journal-title":"Eur Respir J"},{"key":"10498_CR53","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1183\/09031936.03.00008003","volume":"22","author":"MM Hoeper","year":"2003","unstructured":"Hoeper MM, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 2003;22:330\u20134.","journal-title":"Eur Respir J"},{"key":"10498_CR54","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.4065\/78.10.1207","volume":"78","author":"S Bhatia","year":"2003","unstructured":"Bhatia S, Frantz RP, Severson CJ, Durst LA, McGoon MD. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc 2003;78:1207\u201313.","journal-title":"Mayo Clin Proc"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-006-0498-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-006-0498-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-006-0498-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T13:27:57Z","timestamp":1559222877000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-006-0498-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["10498"],"URL":"https:\/\/doi.org\/10.1007\/s10557-006-0498-3","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}